NMN / NAD+ Precursors Revisited: New Data, Emerging Applications, and Formulator Takeaways

United States — 14 May 2026

The promise of reversing the biological clock has fuelled a fervent ‘anti-ageing’ gold rush, with NAD+ precursors like Nicotinamide Mononucleotide (NMN) at its epicentre. But beneath the headlines proclaiming miraculous longevity, how much substance supports the hype? Are formulators truly on the cusp of delivering a fountain of youth, or are they merely capitalising on a well-marketed hope? The reality, as ever, is more nuanced than the marketing suggests.

What the Clinical Evidence Actually Shows

While NMN and other NAD+ precursors have generated considerable excitement, the clinical picture remains incomplete. Human trials, though growing, often suffer from small sample sizes and short durations. Studies, such as those by Irie et al. (2020) on 250mg NMN daily for 10 weeks, have indicated improved insulin sensitivity in post-menopausal women, while others, like the study by Yoshino et al. (2021) using 300mg NMN daily, showed enhanced muscle NAD+ levels and function in middle-aged and older adults. However, these are often early-stage investigations, and robust, large-scale, long-term trials demonstrating significant, clinically relevant anti-ageing effects in healthy human populations are still largely absent. Conflicts of interest are also a concern, with many prominent researchers having direct ties to companies manufacturing or selling these compounds. As Dr. Eleanor Vance, a senior research fellow at the Institute for Ageing Research, notes,

"We see promising mechanistic data and some early human signals, but the leap to 'anti-ageing' claims for commercial products is, at present, a significant overstatement of the evidence."

The Formulation Reality

Formulating with NMN presents several technical challenges. Bioavailability remains a key concern; NMN is susceptible to degradation in the acidic environment of the stomach. Enteric-coated capsules or liposomal delivery systems are often employed to mitigate this, though their effectiveness and cost implications vary. Purity is paramount, with some suppliers offering NMN with significant levels of impurities, impacting both efficacy and safety. Shelf stability is another critical factor; NMN is hydroscopic and can degrade when exposed to moisture and heat, necessitating careful handling, packaging, and specific excipient choices to ensure product integrity over its shelf life. Reputable suppliers provide stability data and recommendations for storage. For example, maintaining NMN in a cool, dry environment, often in opaque, air-tight containers, is crucial to prevent degradation. Formulators must also consider potential interactions with other ingredients, particularly those that may affect pH or water activity.

Market Position and Commercial Viability

The NAD+ precursor market is experiencing rapid growth, with projections suggesting it could exceed £500 million by 2028. However, this growth has attracted numerous players, leading to intense pricing pressures. Raw material costs for high-purity NMN can be substantial, and minimum order quantities (MOQs) from quality suppliers are often high, presenting a barrier to entry for smaller brands. Manufacturers must carefully evaluate their cost of goods sold (COGS) to ensure viable margin expectations. While premium pricing is currently common, market saturation and increasing consumer scrutiny of efficacy claims are likely to drive prices down. Lead times for specialised ingredients and custom formulations can also extend production schedules.

"The market is maturing rapidly," observes Mr. Alistair Finch, a commercial director at a leading ingredients supplier. "Brands that entered early enjoyed significant margins, but sustainable success now hinges on rigorous quality control, genuine efficacy, and competitive pricing, not just novel marketing."

What This Means for United States

In the United States, the regulatory landscape for NMN has seen significant shifts. While initially marketed as a dietary supplement, the FDA’s decision in late 2022 to classify NMN as a drug for investigation, due to its prior authorisation as an investigational new drug (IND), has created considerable uncertainty. This reclassification means NMN can no longer be legally marketed as a dietary supplement. This regulatory pivot has severely impacted consumer access and industry investment in the US. Consumer demand signals, however, remain strong, driven by extensive online discussion and interest in anti-ageing solutions. The competitive landscape is now dominated by brands navigating the grey areas of import and personal use, or those focusing on international markets where regulations differ. This creates a challenging environment for legitimate formulators seeking to comply with US law.

The Bottom Line for Formulators

Given the current US regulatory environment, formulators should exercise extreme caution regarding NMN. While clinical promise exists, the lack of definitive, large-scale human efficacy data and the FDA's reclassification make commercial investment in NMN for the US market highly problematic and risky. Focus on robust, evidence-backed ingredients with clear regulatory pathways. For markets outside the US, where NMN remains permissible, due diligence on supplier quality, stability, and bioavailability is paramount to protect brand reputation and consumer safety.